Lineage Cell Therapeutics: Mixed Q3 Results

Lineage Cell Therapeutics reported a third-quarter loss of $30 million, missing Wall Streets expectations, but surpassed revenue forecasts with $3.7 million, offering a mixed financial picture in the competitive biotechnology sector.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.